Clinical Trial Detail

NCT ID NCT02221310
Title Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors New York Medical College

myelodysplastic syndrome

acute myeloid leukemia


Busulfan + Cyclophosphamide + Gemtuzumab ozogamicin

Age Groups: adult child

No variant requirements are available.